- Home
- TBPH vs DJCO Comparison
TBPH vs DJCO Comparison
Compare TBPH & DJCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBPH | DJCO |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 706.2M |
| IPO Year | 2013 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TBPH | DJCO |
|---|---|---|
| Price | $16.77 | $524.59 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.40 | N/A |
| AVG Volume (30 Days) | ★ 402.7K | 63.8K |
| Earning Date | 05-04-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | 43.50 |
| EPS | ★ 2.06 | N/A |
| Revenue | $15,386,000.00 | ★ $41,384,000.00 |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.33 | $348.63 |
| 52 Week High | $21.03 | $674.75 |
Technical Indicators
Market Signals| Indicator | TBPH | DJCO |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 50.60 |
| Support Level | $13.41 | $485.65 |
| Resistance Level | $17.24 | $559.97 |
| Average True Range (ATR) | 0.41 | 26.21 |
| MACD | 0.02 | -0.63 |
| Stochastic Oscillator | 57.01 | 43.65 |
Price Performance
Historical ComparisonAbout TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.